Confidence is the new buzz
Disclosures: Zobair Younossi: Nothing to Disclose, Alexandra Ellis: Stratevi, LLC: Employee, Jackie Lee: Intercept: Employee of Stratevi, LLC, which received funding from Inter, Leona Bessonova: Nothing to Disclose, Radhika Nair: Intercept Pharma: Employee, Sanofi: Employee, Elizabeth Potente: Nothing to Disclose, Robert Gish: please see full disclosures document: Consultant 2354 IMPROVING KNOWLEDGE IN PBC MANAGEMENT BEYOND FIRST-LINE THERAPY: STRUCTURED LEARNING INCREASES COMPETENCE AND CONFIDENCE S Christy Rohani-Montez 1 Marinella Calle 1 Jrn Schattenberg 2 David Jones 3 , 1 Medscape Education Global, 2 University Medical Center Homburg, 3 Newcastle University, UK Background: Up to ~40% of patients with PBC have an inadequate response or poor tolerability to UDCA leading to an increased risk of end-stage liver disease
The importance of glucose-dependent insulinotropic polypeptide receptor activation for the effects of tirzepatide
Half-life comparison across GLP-1 medications Different GLP-1 medications have different pharmacokinetic profiles
GLP-1s for Small Amounts of Weight Loss
